Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Sculpher

Showing results (61-70 of 174) with videos related to

Pageof 18
Sort By:
Health Economics|February 1, 2017
Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research NeedsClaire Rothery, Karl Claxton, Stephen Palmer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2016
The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 TrialSebastian Hinde, David Epstein, Adrian Cook, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|April 24, 2016
How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral AnticoagulantsRita Faria, Simon Walker, Sophie Whyte, et al.
Applied Health Economics and Health Policy|February 11, 2005
The use of probabilistic decision models in technology assessment : the case of total hip replacementAndrew Briggs, Mark Sculpher, Jill Dawson, et al.
Pharmacoeconomics|May 19, 2006
Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the Medical Research Council LU19 trialLaura Bojke, Mark Sculpher, Richard Stephens, et al.
Journal of the International AIDS Society|November 14, 2014
Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patientsLars Oddershede, Simon Walker, Nicholas Paton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 5, 2026
Alternative pricing policies for multi-indication products: a quantitative analysisBeth S Woods, Carlos Rojas Roque, Claire Rothery, et al.
Advances in Therapy|February 17, 2017
Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled TrialAlison Griffiths, Noman Paracha, Andrew Davies, et al.
Journal of Medical Economics|January 24, 2013
Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and TurkeyAndrew Davies, Ameet Bakhai, Claude Schmitt, et al.
Plos Neglected Tropical Diseases|June 13, 2022
Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimatesSakshi Mohan, Paul Revill, Stefano Malvolti, et al.
Pageof 18

Showing results (61-70 of 174) with videos related to

Sort By:
Pageof 18
Health Economics|February 1, 2017
Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research NeedsClaire Rothery, Karl Claxton, Stephen Palmer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2016
The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 TrialSebastian Hinde, David Epstein, Adrian Cook, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|April 24, 2016
How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral AnticoagulantsRita Faria, Simon Walker, Sophie Whyte, et al.
Applied Health Economics and Health Policy|February 11, 2005
The use of probabilistic decision models in technology assessment : the case of total hip replacementAndrew Briggs, Mark Sculpher, Jill Dawson, et al.
Pharmacoeconomics|May 19, 2006
Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the Medical Research Council LU19 trialLaura Bojke, Mark Sculpher, Richard Stephens, et al.
Journal of the International AIDS Society|November 14, 2014
Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patientsLars Oddershede, Simon Walker, Nicholas Paton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 5, 2026
Alternative pricing policies for multi-indication products: a quantitative analysisBeth S Woods, Carlos Rojas Roque, Claire Rothery, et al.
Advances in Therapy|February 17, 2017
Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled TrialAlison Griffiths, Noman Paracha, Andrew Davies, et al.
Journal of Medical Economics|January 24, 2013
Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and TurkeyAndrew Davies, Ameet Bakhai, Claude Schmitt, et al.
Plos Neglected Tropical Diseases|June 13, 2022
Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimatesSakshi Mohan, Paul Revill, Stefano Malvolti, et al.
Pageof 18